11452 Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 

5. China Patent Application No.: 

201880032676.5, filed Date: May 15, 

2018 (E–017–2017–0–CN–05); 

6. European Patent Application No.: 

18733012.1, filed May 15, 2018 (E–017– 

2017–0–EP–06); 

7. Japan Patent Application No.: 

2019–563082, filed November 13, 2019 

(E–017–2017–0–JP–07); 

8. Korea Patent Application No.: 

2019–7017289, filed December 13, 2019, 

(E–017–2017–0–KR–08); 

9. Singapore Patent Application No.: 

11201910499V, filed November 11, 2019 

(E–017–2017–0–SG–09); 

10. United States Patent Application 

No.: 16/613,187, filed November 13, 

2019 (E–017–2017–0–US–10); 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

fields of use may be limited to the 

following: 

‘‘Development, manufacture and 

commercialization of chimeric antigen 

receptor T cell (CAR–T) 

immunotherapies for the treatment of B 

cell malignancies, wherein the T cells 

are: 

1. Manufactured ex vivo; 

2. Not engineered to overexpress 

CD47; 

3. Engineered to express a CAR that 

targets CD22 via the m971 scFv in 

combination with both: 

a. Binders, CARs, or other receptors 

targeting: CD19, CD20, CD79b, or any 

combination thereof; and 

b. At least one of the following: 

—A technology to activate CD2 

signaling in the CAR T cell, and/or 

—Manufacturing of the cell product 

using the Storage by Actuated 

Shuttling (StASh) 

Where ‘‘ex vivo’’ specifically means 

where the cells or tissue are removed 

from a healthy donor (in the case of 

allogeneic therapy) or the patient (in the 

case of autologous therapy), modified ex 

vivo and then, implanted, transplanted, 

infused, or transferred into the patient. 

For purposes of clarity, specifically 

excluded from these Fields of Use are 

the following: 

1. Allogeneically-derived CAR–T 

immunotherapies that have been 

engineered to overexpress CD47; 

2. CAR–T immunotherapies wherein 

the CAR–T cells are manufactured 

within the patient via gene therapy 

vectors delivered to the patient (in vivo 

CAR–T immunotherapies); 

3. Autologously-derived CAR–T 

immunotherapies that have been 

engineered to be specific for CD19, 

CD20, and CD22 (via the m971 scFv) 

absent the engineering of the CAR–T 

therapies to activate CD2 signaling and/ 

or StASh as described in the Fields of 

Use 3(b) above; 

4. CAR–T immunotherapies wherein 

the CAR–T cells are engineered to 

express a bispecific CAR that is 

engineered to bind to CD19 and CD22, 

as described in HHS Ref. E–106–2015 

and encompassing the m971 scFv and 

the CD22 CAR.’’ 

The government-owned technologies 

that are contemplated in this proposed 

license are CAR therapies that target 

CD22 by utilizing the anti-CD22 binder 

known as m971 alone. The E–080–2008 

technology encompasses the m971 

binder, while E–291–2012 describes a 

CAR encompassing the m971 binder. 

Additionally, E–017–2017 describes a 

bicistronic CAR vector that 

encompasses the CD22-targeting m971 

CAR and a CAR that targets CD19. CD22 

is expressed on the surface of B cells in 

B cell malignancies and CD22-targeting 

CAR–T has shown early promise in 

clinical trials for ALL and NHL both as 

a monospecific and multispecific 

therapy. Targeting CD22 in combination 

with other B cell antigens (CD19, CD20, 

and/or CD79b in this instance) can lead 

to more effective CAR–T cell therapies. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: February 23, 2022. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2022–04245 Filed 2–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Research 

Projects in Cancer Systems Biology (CSBC 

Research Projects) (U01). 

Date: March 31, 2022. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W234, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Adriana Stoica, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

7W234, Rockville, Maryland 20850, 240– 

276–6368, Stoicaa2@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–1 NCI 

Clinical and Translational R21 and Omnibus 

R03 Review. 

Date: March 31, 2022. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W602, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Delia Tang, M.D., 

Scientific Review Officer, Resources Training 

and Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W602, 

Rockville, Maryland 20850, 240–276–6456, 

tangd@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Social and 

Behavioral Intervention Research to Address 

Modifiable Risk Factors for Cancer in Rural 

Populations (R01). 

Date: May 5, 2022. 

Time: 10:00 a.m. to 4:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 


jspears on DSK121TN23PROD with NOTICES1
Federal Register / Vol. 87, No. 40 / Tuesday, March 1, 2022 / Notices 11453 

7W618, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Mukesh Kumar, Ph.D., 

Scientific Review Officer, Research Program 

Review Branch, Division of Extramural 

Activities, 9609 Medical Center Drive, Room 

7W618, National Cancer Institute, NIH, 

Rockville, Maryland 20850, 240–276–6611, 

mukesh.kumar3@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 24, 2022. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–04273 Filed 2–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Conference Grant Review R13. 

Date: April 7, 2022. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Tony L. Creazzo, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 207–Q, 

Bethesda, MD 20892–7924, (301) 827–7913, 

creazzotl@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Member Conflict Mentored Career 

Development Awards. 

Date: April 8, 2022. 

Time: 2:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Lindsay M. Garvin, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Suite 208–Y, 

Bethesda, MD 20892, (301) 827–7911, 

lindsay.garvin@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Multi-site Clinical Trial Special Emphasis 

Panel. 

Date: April 19, 2022. 

Time: 1:00 p.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Keary A. Cope, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 209–A, 

Bethesda, MD 20892–7924, (301) 827–7912, 

copeka@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

HEAL Initiative: Opioid Induced Respiratory 

Depression. 

Date: April 27, 2022. 

Time: 11:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Kristin Goltry, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 209–B, 

Bethesda, MD 20892, (301) 435–0297, 

goltrykl@mail.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Pulmonary Trials Cooperative (PTC). 

Date: April 28, 2022. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6705 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Kristen Page, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 209–B, 

Bethesda, MD 20892, (301) 827–7953, 

kristen.page@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood 3Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: February 24, 2022. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–04288 Filed 2–28–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Molecular 

Neurogenetic Labeling and Imaging 

Techniques. 

Date: March 23, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mary G. Schueler, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5214, 

MSC 7846, Bethesda, MD 20892, 301–915– 

6301, marygs@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Speech, Language and 

Communication. 

Date: March 25, 2022. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Sara Louise Hargrave, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

Bethesda, MD 20892, (301) 443–7193, 

hargravesl@mail.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Infectious Diseases and 

Immunology. 

Date: April 4–5, 2022. 

Time: 9:00 a.m. to 6:00 p.m. 


jspears on DSK121TN23PROD with NOTICES1